Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REDIPEG is a medical device (classified as CE 0426) developed by the Italian pharmaceutical company Aurora Biofarma for the treatment of chronic constipation and associated gastrointestinal symptoms such as bloating and excessive gas production. The product is a combination of Macrogol 4000 (polyethylene glycol 4000) and Simeticone. Macrogol 4000 functions as an osmotic laxative, attracting water into the intestinal lumen to soften stools and increase their volume, thereby facilitating evacuation without causing cramping or mucosal irritation. Simeticone acts as an anti-foaming agent that reduces the surface tension of gas bubbles in the digestive tract, aiding in their absorption or elimination. REDIPEG is formulated as ready-to-drink orange-flavored stick packs and is indicated for use in both adults and children from one year of age.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on REDIPEG.